ATC Group: A02BC01 Omeprazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BC01 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A02 Drugs for acid related disorders
4 A02BC Proton pump inhibitors
5 A02BC01 Omeprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 20 mg
PAREN - Parenteral 20 mg

Active ingredients in A02BC01

Active Ingredient Description

Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.

Related product monographs

Title Information Source Document Type  
LOSEC Capsule, Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
MEDOPRAZOLE Gastro-resistant capsule, hard Υπουργείο Υγείας (CY) MPI, EU: SmPC
OMEPRAZOLE Gastro-resistant capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OMEPRAZOLE Powder for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OMEZ Capsule Health Products Regulatory Authority (ZA) MPI, Generic
PEDIPPI Powder for oral suspension Health Products Regulatory Authority (IE) MPI, EU: SmPC
PRILOSEC Granule for delayed-release oral suspension FDA, National Drug Code (US) MPI, US: SPL/PLR
ULCESEP Hard gelatin capsule Medicines Authority (MT) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Finland (FI)

France (FR)

Germany (DE)

Israel (IL)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.